{"name":"Phreesia","slug":"phreesia","ticker":"PHR","exchange":"NYSE","domain":"phreesia.com","description":"Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.","hq":"Raleigh, NC","founded":0,"employees":"1789","ceo":"Chaim Indig","sector":"Digital Health / Health IT","stockPrice":9.13,"stockChange":0.07,"stockChangePercent":0.77,"marketCap":"$555M","metrics":{"revenue":419813000,"revenueGrowth":15.9,"grossMargin":67.9,"rdSpend":117364000,"netIncome":-58527000,"cash":72139000,"dividendYield":0,"peRatio":228.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Phreesia Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Phreesia reported revenue of $123.1 million for the fourth quarter of 2023, a 24% increase from the same period in 2022.","drugName":"","sentiment":"positive"},{"date":"2023-11-14","type":"deal","headline":"Phreesia Partners with Dermatology Associates of Atlanta","summary":"Phreesia has partnered with Dermatology Associates of Atlanta to provide its digital patient engagement platform to the dermatology practice.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNTE8yTnRMNXkyRW1WTnZ2WDJIcVNtSHBIaXF6Zjh5bC1CeUljUmQ1bDJhbFRJcmYzc0dqTGxvd05MQmt3c3N0YzEta253Tkc3WkppOXZ6SWFCeXhycnhzNDBGWDFiVUJoNlhzelRYVW9pYVZGTWpzb2VqSjQ0WkJzSDdkUng0d2VFMjZpM0xqM0pyNlJsTEpyZ293NDZlWGM5RnF1WmxOMkpLYUd5c2VSVnM1Q3ZXYlRLNjNOU0VwOS1QeF9TbFVzdVRKNWI5RG9oMURV?oc=5","date":"2026-04-06","type":"pipeline","source":"Investing.com","summary":"Raymond James cuts Phreesia stock price target on pharma ad headwinds - Investing.com","headline":"Raymond James cuts Phreesia stock price target on pharma ad headwinds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPU1FnY1hTTWhLUW1KMWlCMklQOW1MNG43M1ByQXdNRlgwMHdicXF2cTNETGVka1RFcURITzJGaWhURkhya3kwQ3hxT0FjdHJERlFrZWV1OHlTRllZUDVXck13NGlackRyblRUZmRjWEpOaTdQdXFIbXNOVVZscjM4cm9QSGs5SlJzTDliMjJSQmVIYWpSd1lLUFFpTUVVSHd2RHBxWkVoUDlWbnFWUmk2WE0xbndkRHdoYTIwSXFTLUhiZVR1WTlYaGJITWVQVnZ2Yll1RA?oc=5","date":"2026-04-05","type":"earnings","source":"Sahm","summary":"A Look At Phreesia (PHR) Valuation After Fiscal 2027 Guidance Cut And Analyst Downgrades - Sahm","headline":"A Look At Phreesia (PHR) Valuation After Fiscal 2027 Guidance Cut And Analyst Downgrades","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"earnings","source":"simplywall.st","summary":"A Look At Phreesia (PHR) Valuation After Fiscal 2027 Guidance Cut And Analyst Downgrades - simplywall.st","headline":"A Look At Phreesia (PHR) Valuation After Fiscal 2027 Guidance Cut And Analyst Downgrades","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOZmhKbVFWV0Y4T1EyYnl3bUdQT3MwUTc3U0FtTXBmQ3BxNGNEYVF3Y0dLQV8xM2lvQS1qQjhzeWx3RS1VaWZzWlNCTk9XSWRIZkVxYlBhUndBQzgtWHczZ1ExZVZHck1oVkE4bndsOE5BcElzZHAwbVpuMUozcDVKakdzeFpyeDBmbl9sWlljTGNBOVFMeXdfWlZvazFJOVVpQUc0aGUzOVZQQ2pmZkN3T1NyR0ZQVFNlLXBGaUVnbmdkYkVVYk45SlJiSzU0b1I2T3FRSzRYX3JmbEpsenlxRDBMaVkwTnFUaXBYRm1uMnEwTVVseDVrbWU5TQ?oc=5","date":"2026-04-03","type":"earnings","source":"Sahm","summary":"Phreesia (PHR) Is Down 25.5% After Cutting 2027 Revenue Outlook Amid Pharma Spend Uncertainty – Has The Bull Case Changed? - Sahm","headline":"Phreesia (PHR) Is Down 25.5% After Cutting 2027 Revenue Outlook Amid Pharma Spend Uncertainty – Has The Bull Case Change","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNbjlQYnUxRHctM1ZENmgycXFlanR5b3BMS3JjekVaSVkzZU8ta0txdUtHLU5fMjB5Uk50Rk1DS2FnVVRqSlpXTVE5TWFydFJoYjFTUlJnX3RkUlo4eDVCekFNbTlhTjhHUTZpUndCU3RITUpmY0xKVDBZYnJxcHpsNWtTQk9wQWZRNHpnV0VWZ0xsOXRoT0hIM1RyUTczcVhPNEEwdlFRaVJIWkItVjVVai1wV29BM0J2ajE4NUNnLVRmWV9uUks4SWZMaENuRVpNcmV4bkhIQVppZmlxb3ZjWHB1TDZhdlUwR2c?oc=5","date":"2026-04-03","type":"pipeline","source":"Business Wire","summary":"PHR Investors Have Opportunity to Join Phreesia, Inc. Fraud Investigation with the Schall Law Firm - Business Wire","headline":"PHR Investors Have Opportunity to Join Phreesia, Inc. Fraud Investigation with the Schall Law Firm","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNdTV6bm1rMThvN1pHekVjcVdDQmJJLXdVdFgyRmVMTzJxaEJ1eEhRUVN2UEM5cEoyTU9nb2htTDJ2UC1taE5ORFpYdFBXb2VDUm9vbUhwV25TeGxYdjRUME1qYW1nOTZQUmJCSUdreHVWNEVfRUR5Z3kxS1Z5RE5TLTdaNzdWVDBLcVh0aG1jd1JzYzgxaVpfdXBPRGlsRUpyaFppM2lBY3ZNR19NR0RVaUVfanZhNHZWazcwNGJydG9mcjB5S25WWmkzd0tINlR6NFNKTGRQclRrU3BsWmJsdldHVWZqZTJMNUVwLVNVVHVsbGlId0hfMHc5T1pHZXpIcU9meldnLVJtUVlXZ1JmVEtWUFpaYWQ3Zk1ndlhSanRQQQ?oc=5","date":"2026-04-01","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Conflicted on These Healthcare Names: Phreesia (PHR), Viridian Therapeutics (VRDN) and Orthofix Medical (OFIX) - The Globe and Mail","headline":"Analysts Conflicted on These Healthcare Names: Phreesia (PHR), Viridian Therapeutics (VRDN) and Orthofix Medical (OFIX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOdVpyVHU0TnotXzgyT09tZmhKT2Z3TW5QSnoyT1RDd0N2bmEzWlVWR0lVblI5SGN1M3Z6RlRVSFBlWnVzbzY4QWxyY01ZQjVFTThUOUR3YzFuS2sxdTVPUERKRlB2Sm9KMkJfZ0NCdW1PNFFVb29LcW9DUTVVbExKNlJSaldpTFQ3M0pvSXlLT241SFNjRy1zblBZWW9vYWpPRGd4MVdEc0ZvcnRkVzhXcDk4UmRyeVlwU2REeUF1ZDY?oc=5","date":"2026-03-31","type":"earnings","source":"Trefis","summary":"Phreesia Stock Pre-Market (-24%): Slashes Full-Year Revenue Guidance - Trefis","headline":"Phreesia Stock Pre-Market (-24%): Slashes Full-Year Revenue Guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNd3AycDFEUWZESlFOc1ZldW5OS1IxS0pOTE40MWpvZlIwQUZDbmV0M1c3OUNaRjg2bWMyQV83ZjlHTnVOU3d1ajEtZURHTHpuYWdxMEhOMUFtV3ZBTzlnSDJwaV9fa1U2REhYYjhrUHVkZ05POTIwSDZRcmIzbzNGQ3dJUF9iZGk4UXduTjdzOXhBTVdsQ3RjWnQyQUtla1psVXRnVGJKQzJrZW9WeTBDYTZCdmloUXloN3JtajJ4T0xuS2s?oc=5","date":"2026-03-31","type":"pipeline","source":"Investing.com South Africa","summary":"Phreesia stock holds at Outperform as pharma outlook dims guidance By Investing.com - Investing.com South Africa","headline":"Phreesia stock holds at Outperform as pharma outlook dims guidance By Investing.com","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNZTN2aTlCYVVQTnJBSnlhRGpDOWZqTkpaZmV0eVdBT3BYaVJXTVVDcklScG9qejBiQjR5QmZoVXdPY20xTG9JN0l0SzNncldNM3U0LUFGcUdEMmROYjJELVl1dXZia2NSTm9UWGxJdVdSTXRoSG5iSGtldlJvdHVoUVMxQzlZVmRSWFpMRHFCLTU3ZTdYRVp4bGwzYkNpN08tdHY3S2h1UG1Uelg1ejJEM184azJDaDI1ck9Oc3M1WHQ1Y29KY0g0UU5JeDB5TkJHT1hOczhvMkdUNTMwS1dxUmFMVXptMzhuVWViLWtMT2t1WTFxSjRkMnQxNmJabGNQbXZvbUF5N3lIb05Gd1hBOUNn?oc=5","date":"2026-03-30","type":"regulatory","source":"TradingView","summary":"PHR: FY27 revenue guidance cut on pharma headwinds, but margin and cash flow outlooks remain robust - TradingView","headline":"PHR: FY27 revenue guidance cut on pharma headwinds, but margin and cash flow outlooks remain robust","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQM19TUE1CLVBnME90RDNRQVI3bjUxRVBfU2lqTW5ZNXdYcmV2X3kzcFdnTy1aR0wwdzE0R1FfQVpBRUQtdXhOcnJLVzk0OUJYdmFESnV4Yk84Wk1yT2kwRTY2UHUxYzVnNlZ4ZldNekVJUlJDTk9nM0oyTWxBbGxOTDdjYklDUQ?oc=5","date":"2026-03-12","type":"pipeline","source":"Yahoo Finance","summary":"How The Phreesia (PHR) Story Is Shifting As Price Targets Fall And AI Tools Grow - Yahoo Finance","headline":"How The Phreesia (PHR) Story Is Shifting As Price Targets Fall And AI Tools Grow","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Zocdoc","Teladoc Health","American Well"],"therapeuticFocus":["Dermatology","Primary Care"],"financials":{"source":"sec_edgar","revenue":419813000,"revenuePeriod":"2025-01-31","revenueHistory":[{"value":419813000,"period":"2025-01-31"},{"value":356299000,"period":"2024-01-31"},{"value":356299000,"period":"2024-01-31"},{"value":280910000,"period":"2023-01-31"},{"value":280910000,"period":"2023-01-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":117364000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-58527000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":388415000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":9.13,"previousClose":9.06,"fiftyTwoWeekHigh":32.76,"fiftyTwoWeekLow":7.77,"fiftyTwoWeekRange":"7.77 - 32.76","fiftyDayAverage":12.01,"twoHundredDayAverage":20.57,"beta":0.85,"enterpriseValue":580823360,"forwardPE":5.4,"priceToBook":1.64,"priceToSales":1.15,"enterpriseToRevenue":1.21,"enterpriseToEbitda":28.11,"pegRatio":0,"ebitda":20665000,"ebitdaMargin":4.3,"freeCashflow":55702248,"operatingCashflow":78814000,"totalDebt":102449000,"debtToEquity":30.4,"currentRatio":1.53,"returnOnAssets":0.3,"returnOnEquity":0.8,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":18,"targetMeanPrice":16.44,"targetHighPrice":24,"targetLowPrice":10,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.7,"institutionHeldPercent":114.7,"sharesOutstanding":60763065,"floatShares":48648733,"sharesShort":4404667,"shortRatio":2.71,"shortPercentOfFloat":7.3,"epsTrailing":0.04,"epsForward":1.7,"revenuePerShare":8.04,"bookValue":5.56,"officers":[{"age":46,"name":"Mr. Chaim  Indig","title":"Co-Founder, CEO & Director"},{"age":46,"name":"Mr. Evan  Roberts","title":"Co-Founder & President of Provider Solutions"},{"age":51,"name":"Mr. Balaji  Gandhi","title":"Chief Financial Officer"},{"age":54,"name":"Ms. Allison C. Hoffman J.D.","title":"General Counsel & Secretary"},{"age":45,"name":"Mr. David  Linetsky","title":"President of Network Solutions"},{"age":43,"name":"Ms. Yvonne  Hui","title":"Senior VP & Chief Accounting Officer"},{"age":null,"name":"Mr. Jack  Callahan","title":"Chief Technology Officer"},{"age":null,"name":"Ms. Briana  Kearney","title":"Vice President of Marketing"}],"industry":"Health Information Services","irWebsite":"","website":"https://www.phreesia.com","phone":"888 654 7473"}}